Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Goldman Sachs has maintained a Neutral rating for HUTCHMED (China) Ltd (NASDAQ:HCM) and increased its price target from $15.00 to $17.00. HUTCHMED's shares are currently trading at $18.49, which is 2.21% higher than the last 24 hours. The new price target suggests a potential downside of 8.06% from the current share price. HUTCHMED is a biopharmaceutical company focused on cancer and immunological diseases, with a presence in China.
November 10, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs maintains a Neutral rating on HUTCHMED (China) Ltd and raises its price target to $17.00, indicating a potential downside from the current price of $18.49.
The maintenance of a Neutral rating by Goldman Sachs, combined with a price target that is below the current trading price, could lead to a negative perception among investors, potentially putting downward pressure on HCM's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100